Cited 23 times in
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 손주혁 | - |
dc.contributor.author | 최영철 | - |
dc.date.accessioned | 2021-09-29T02:30:58Z | - |
dc.date.available | 2021-09-29T02:30:58Z | - |
dc.date.issued | 2020-05 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184953 | - |
dc.description.abstract | The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment of physician's choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who had received ≤2 chemotherapy lines in the metastatic setting. Here, we report pre-specified analyses of data from Asian (China, Japan, Korea and Taiwan) patients in the study. All patients were randomized 2:1 to olaparib tablets (300 mg twice daily) or single-agent chemotherapy TPC (21-day cycles of either capecitabine, eribulin or vinorelbine). The primary endpoint was progression-free survival assessed by blinded independent central review. The prevalence of gBRCAm in the OlympiAD Asian subgroup screened for study recruitment was 13.5%. Patient demographics and disease characteristics of the Asian subgroup (87/302 patients) were generally well balanced between treatment arms. Asian patients in the olaparib arm achieved longer median progression-free survival, assessed by blinded independent central review, versus the chemotherapy TPC arm (5.7 vs 4.2 months; HR = 0.53 [95% CI: 0.29-0.97]), which was consistent with findings in the global OlympiAD study population. Findings on secondary efficacy and safety/tolerability outcome measures in Asian patients were also similar to those observed in the global OlympiAD study population. The OlympiAD study was not powered to detect race-related differences between treatment groups; however, the consistency of our findings with the global OlympiAD study population suggests that previously reported findings are generalizable to Asian patients. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isPartOf | SCIENTIFIC REPORTS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antineoplastic Agents / therapeutic use* | - |
dc.subject.MESH | Asian Continental Ancestry Group | - |
dc.subject.MESH | Breast Neoplasms / drug therapy* | - |
dc.subject.MESH | Breast Neoplasms / genetics | - |
dc.subject.MESH | Capecitabine / therapeutic use | - |
dc.subject.MESH | Carcinoma / drug therapy | - |
dc.subject.MESH | Carcinoma / genetics | - |
dc.subject.MESH | Carcinoma / secondary* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Furans / therapeutic use | - |
dc.subject.MESH | Gastrointestinal Diseases / chemically induced | - |
dc.subject.MESH | Genes, BRCA1* | - |
dc.subject.MESH | Genes, BRCA2* | - |
dc.subject.MESH | Genes, erbB-2 | - |
dc.subject.MESH | Germ-Line Mutation | - |
dc.subject.MESH | Hematologic Diseases / chemically induced | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kaplan-Meier Estimate | - |
dc.subject.MESH | Ketones / therapeutic use | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Phthalazines / adverse effects | - |
dc.subject.MESH | Phthalazines / therapeutic use* | - |
dc.subject.MESH | Piperazines / adverse effects | - |
dc.subject.MESH | Piperazines / therapeutic use* | - |
dc.subject.MESH | Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use* | - |
dc.subject.MESH | Progression-Free Survival | - |
dc.subject.MESH | Single-Blind Method | - |
dc.subject.MESH | Vinorelbine / therapeutic use | - |
dc.title | Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seock-Ah Im | - |
dc.contributor.googleauthor | Binghe Xu | - |
dc.contributor.googleauthor | Wei Li | - |
dc.contributor.googleauthor | Mark Robson | - |
dc.contributor.googleauthor | Quchang Ouyang | - |
dc.contributor.googleauthor | Dah-Cherng Yeh | - |
dc.contributor.googleauthor | Hiroji Iwata | - |
dc.contributor.googleauthor | Yeon Hee Park | - |
dc.contributor.googleauthor | Joo Hyuk Sohn | - |
dc.contributor.googleauthor | Ling-Ming Tseng | - |
dc.contributor.googleauthor | Carsten Goessl | - |
dc.contributor.googleauthor | Wenting Wu | - |
dc.contributor.googleauthor | Norikazu Masuda | - |
dc.identifier.doi | 10.1038/s41598-020-63033-4 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A04116 | - |
dc.relation.journalcode | J02646 | - |
dc.identifier.eissn | 2045-2322 | - |
dc.identifier.pmid | 32472001 | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | 손주혁 | - |
dc.contributor.affiliatedAuthor | 최영철 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 8753 | - |
dc.identifier.bibliographicCitation | SCIENTIFIC REPORTS, Vol.10(1) : 8753, 2020-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.